Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fructo-oligosaccharides + probiotics
- Development stage
- Unknown
- Lead developer
- Steno Diabetes Center Copenhagen
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
fructo-oligosaccharides + probiotics is a synbiotic mixture consisting of short-chain fructo-oligosaccharides (scFOS) as a prebiotic and a probiotic blend of Lactobacillus reuteri DSM34531, Lactobacillus rhamnosus DSM26357, and Bifidobacterium lactis DSM32269. Developed in collaboration with dsm-firmenich and the Steno Diabetes Center Copenhagen, the synbiotic mix is designed to modulate the gut microbiota, strengthen the intestinal barrier, and reduce systemic inflammation. It has been clinically evaluated in the ProFOS study (NCT04635670) for its potential to improve albuminuria, endothelial function, and markers of nephropathy in individuals with type 1 diabetes and albuminuria.
- Other names
- pre-/probiotic mixsynbiotic mixsynbiotic mixture
Beyond the preview
Go deeper on fructo-oligosaccharides + probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fructo-oligosaccharides + probiotics.